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6* nicotinic acetylcholine receptors (nAChRs) are highly and selectively expressed by mesostriatal dopamine (DA) neurons. These
neurons are thought to mediate several behavioral effects of nicotine, including locomotion, habit learning, and reinforcement. Yet the
functional role of6* nAChRs inmidbrain DA neurons ismostly unknown. The aim of this study was to determine the composition and
in vivo functional role of6* nAChR inmesolimbic DAneurons ofmale rats. Immunoprecipitation and immunopurification techniques
coupled with cell-specific lesions showed that the composition of 6* nAChR in the mesostriatal system is heterogeneous, with (non-
4)62* being predominant in themesolimbic pathway and462* in the nigrostriatal pathway.We verifiedwhether6* receptors
mediate the systemic effects of nicotine on themesolimbicDApathwaybyperfusing the selective antagonists-conotoxinMII (CntxMII)
(3/62* selective) or -conotoxin PIA (CntxPIA) (62* selective) into ventral tegmental area (VTA). The intra-VTA perfusion of
CntxMII or CntxPIAmarkedly decreased systemic nicotine-elicitedDA release in the nucleus accumbens andhabituated locomotion; the
intra-VTA perfusion of CntxMII also decreased the rate of nicotine infusion in the maintenance phase of nicotine, but not of food,
self-administration. Overall, the results of these experiments show that the 62* nAChRs expressed in the VTA are necessary for the
effects of systemic nicotine onDAneuron activity andDA-dependent behaviors such as locomotion and reinforcement, and suggest that
62*-selective compounds capable of crossing the blood–brain barriermay affect the addictive properties of nicotine and therefore be
useful in the treatment of tobacco dependence.
Introduction
Themesostriatal dopamine (DA) pathway is a major brain target
of nicotine. Its ventral [the mesolimbic DA pathway, comprising
cell bodies in the ventral tegmental area (VTA) and terminals in
the nucleus accumbens (nAc) and tuberculum olfactorium] and
dorsal [the nigrostriatal DA pathway, comprising cell bodies in
the substantia nigra and terminals in the caudate–putamen
(CPu)] components both express high levels of nicotinic acetyl-
choline receptors (nAChRs). These receptors are thought to me-
diate several main behavioral effects of nicotine, including the
regulation of locomotor activity and reinforcement in the me-
solimbic component and habit learning in the nigrostriatal com-
ponent (Di Chiara, 2000; Janhunen and Ahtee, 2007).
Neuronal nAChRs comprise a heterogeneous family of pen-
tameric oligomersmade up of combinations of subunits encoded
by at least 11 different genes in mammals. They have been
grouped into two subfamilies based on their phylogenetic, func-
tional, and pharmacological properties (Le Nove`re and Chan-
geux, 1995; Corringer et al., 2000; Gotti et al., 2006), namely the
-bungarotoxin (Bgtx)-sensitive nAChRs (7, 9, and 10 sub-
units) and the Bgtx-insensitive nAChRs (2–6 and 2–4 sub-
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units). These latter subunits can combine to form a number of
functionally and pharmacologically different heteropentamers
consisting of two to four different subunits.
Most nAChR subunits are expressed inmidbrain DA neurons
(Le Nove`re et al., 1996; Charpantier et al., 1998; Azam et al.,
2002). Two main populations of Bgtx-insensitive nAChRs are
expressed by DA cell body/dendrite compartment of the ventral
midbrain, 4(non-6)2* and 62* nAChRs (Klink et al.,
2001; Champtiaux et al., 2003). However, their complete subunit
composition and possible cellular or subcellular heterogeneity
are not known. Much more is known on the composition of
nAChRs expressed by striatal DA terminals. Converging immu-
nochemical and neurochemical evidence (Grady et al., 2007)
demonstrate the presence of four main populations: 42,
452, 62(3), and 462(3) nAChRs. Less is known on
their regional and cellular heterogeneity. Yet a recent paper
showed that 62 responses dominate in the nAc but not in the
CPu (Exley et al., 2008).
Much evidence has been collected on the functions of 62*
nAChRs in in vitro and ex vivo preparations (Champtiaux et al.,
2003; Salminen et al., 2004; Grady et al., 2007; Drenan et al.,
2008). In addition, some recent papers have started to elucidate
the functional role of6* nAChRs in vivo, showing their involve-
ment in nicotine-elicited locomotion (Drenan et al., 2008) and
nicotine self-administration (Pons et al., 2008; Brunzell et al.,
2010).
The purpose of the present experiments is to assess the role of
62* nAChRs of the mesolimbic DA pathway in mediating in
vivo neurochemical and behavioral effects of systemic nicotine.
With this aim, we identified nAChR composition in these neu-
rons, dissecting the different components of the mesostriatal sys-
tem, in particular distinguishing the nigrostriatal from the
mesolimbicDApathway, and examined the effects of the selective
62* nAChR antagonists -conotoxin MII (CntxMII) and
-conotoxin PIA (CntxPIA) (Dowell et al., 2003) administered
into the VTA or the nAc through microdialysis cannulae, on
main neurochemical and behavioral effects of systemic nicotine.
Materials andMethods
Animals and materials
Adult male pathogen-free Sprague Dawley rats (Charles River) were
used. All animal experimentation was conducted in accordance with
the European Communities Council Directive of 24 November 1986
(86/609/EEC).
(/)[ 3H]Epibatidine (Epi) [specific activity (s.a.), 50–66Ci/mmol]
and [N-methyl- 3H]nisoxetine (s.a., 82 Ci/mmol) were purchased from
GE Healthcare, 125I-Epi (s.a., 2200 Ci/mmol) and 3H-labeled ()-2--
carbomethoxy-3--(4-fluorophenyl)tropane ([ 3H]WIN 35,428) (s.a.,
86 Ci/mmol) were from PerkinElmer, and nonradioactive ligands
were from Sigma-Aldrich. CntxMII, -conotoxin MII [H9A,L15A]
(CntxMIImod) (McIntosh et al., 2004), and CntxPIA were custom
synthesized by NeoMPS. Complete Mini, a specific mixture of pepti-
dase inhibitors, was obtained from Roche Diagnostic. Aprotinin, leu-
peptin, pepstatin, and phenylmethylsulfonyl fluoride (PMSF) were
purchased from Sigma-Aldrich.
In self-administration experiments, nicotine hydrogen tartrate (Sigma-
Aldrich) was dissolved in heparinized bacteriostatic saline (0.9% NaCl
plus 0.9% benzyl alcohol plus 1 IU/ml heparin), and pH was adjusted to
7.4 with NaOH. Nicotine unit doses are expressed as milligrams of free
base/kilogram of body weight/infusion.
Immunoprecipitation and immunopurification experiments
Antibody production and characterization. The polyclonal antibodies
against the 2, 3, 4, 5, 6, 2, 3, and 4 nAChR subunits were
produced in rabbit as previously described (Gotti et al., 2005a,b) and
affinity purified. The peptides obtained from mouse, rat, or human se-
quences were located in the putative cytoplasmic (CYT) loop between
M3 and M4 and/or at the C terminal. For almost all of the subunits, we
raised antisera directed against two separate peptides of the same subunit
and the immunoprecipitation values reported are the mean of results
obtained using both antisera. For a full characterization of nAChR-
subunit antibodies, see Grady et al. (2009), their supplemental Table 1.
The affinity-purified antisera were bound to CNBr-activated Sepharose
at a concentration of 1 mg/ml, and the columns used for subtype
immunopurification.
Characterization of antibody specificity was performed using nAChR
subunit knock-out mice, brain region extracts and cells transfected with
subunit cDNAs as described previously (Zoli et al., 2002; Champtiaux et
al., 2003; Moretti et al., 2004; Gotti et al., 2005a).
6-Hydroxydopamine andN-2-chlorethyl-N-ethyl-2-bromobenzylamine
lesions and eye enucleation. Unilateral denervation of mesostriatal DA
pathways was performed by injecting the selective neurotoxin 6-hydro-
xydopamine (6OHDA) (10g/4l) in the medial forebrain bundle [co-
ordinates from bregma: anterior (A),4 mm; lateral (L), 1.8 mm; deep
(D),7.5 mm] (Paxinos and Watson, 2007). [ 3H]WIN 35,428 binding
was determined individually in dorsal and ventral striata and ventral
midbrain from unlesioned and 6OHDA-lesioned rats using a saturat-
ing concentration of 100 nM [ 3H]WIN 35,428 in the presence or
absence of 10 M GBR 12935 [1-(2-(diphenylmethoxy)ethyl)-4-(3-
phenylpropyl)piperazine]. 6OHDA-lesioned tissues with a decrease
of [ 3H]WIN 35,428 80% were discarded.
Noradrenaline (NA) denervation was obtained by injection of the se-
lective toxinN-2-chlorethyl-N-ethyl-2-bromobenzylamine (DSP-4) (50
mg/kg, i.p.; Sigma-Aldrich). The animals were killed 14 d after the toxin
injection, and the dorsal and ventral striatum as well as ventral midbrain
were dissected and rapidly frozen. Binding of [N-methyl- 3H]nisoxetine,
a selective ligand for noradrenaline transporter, was used to assess the
extent of NA terminal degeneration.
Bilateral enucleation of the eyes was performed to examine the effects
of retinal deafferentation on nAChR subtype expression in mesostriatal
regions. Enucleation was performed under deep anesthesia with halo-
thane (Merial Italia). The extraocularmuscles were cut until reaching the
optic nerve. The optic nerve was exposed and cut, and the eye was com-
pletely removed. The remaining cavity was filled with Gelfoam embed-
ded in xylocaine and sealed with cyanoacrylamide gel. The enucleated
rats were killed 14 d after the enucleation to allow for degeneration of
retinogeniculate and retinocollicular pathways (Lund et al., 1976).
Brain region dissection. Selected regions were manually dissected from
fresh brain coronal sections. Dorsal and ventral striatum were dissected
from coronal sections that span from bregma level 0 to2.5mm. Dorsal
striatum comprised the CPu, whereas ventral striatum comprised nAc,
rostral ventral pallidum, and tuberculum olfactorium. Ventral midbrain
was dissected from coronal sections that span from bregma level4.8 to
6.0 mm, taking away the interpeduncular nucleus.
Preparation of membranes and 2% Triton X-100 extracts. The tissues
were immediately frozen in liquid nitrogen and stored at80°C for later
use. In every experiment, the tissues (0.2 g)were homogenized in 10ml of
50 mM sodium phosphate, pH 7.4, 1 M NaCl, 2 mM EDTA, 2 mM EGTA,
and 2mMPMSFwith a Potter homogenizer. The homogenates were then
diluted and centrifuged for 1.5 h at 60,000  g. The procedures of ho-
mogenization, dilution, and centrifugation of the total membranes were
performed twice, after which the pellets were collected, rapidly rinsed
with 50 mM Tris-HCl, pH 7, 120 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2.5
mM CaCl2, and 2 mM PMSF, and then resuspended in the same buffer
containing a mixture of 20 g/ml of each of the following protease in-
hibitors: leupeptin, bestatin, pepstatin A, and aprotinin. Triton X-100 at
a final concentration of 2% was added to the washed membranes, which
were extracted for 2 h at 4°C. The extracts were then centrifuged for 1.5 h
at 60,000 g and recovered, and an aliquot of the resultant supernatants
was collected for protein measurement using the BCA protein assay
(Pierce) with bovine serum albumin as the standard.
[N-methyl-3H]Nisoxetine binding. The binding of nisoxetine to mem-
branes, obtained from control and treated animals, was performed as
previously described (Cheetham et al., 1996) with minor modifications.
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Briefly, tissues were homogenized using a Potter in ice-cold 50 mM Tris-
HCl, pH 7.4, containing 120 mM NaCl and 5 mM KCl, diluted, and
centrifuged as described by Cheetham et al. (1996). Saturation binding
experiments were performed using final [N-methyl- 3H]nisoxetine con-
centrations ranging from 0.1 to 15 nM at 4°C for 4 h. Nonspecific binding
(averaging 10–20% of total binding) was determined in parallel by
means of incubation in the presence of 1 M unlabeled nisoxetine
(Sigma-Aldrich). At the end of the incubation, the samples were filtered
on a GFC filter soaked in 0.5% polyethylenimine and washed with 15 ml
of 10 mM sodium phosphate, pH 7.4, plus 50 mM NaCl, and the filters
were counted in a beta counter.
125I--bungarotoxin binding. Binding experiments were performed by
incubating striatal or midbrain membranes overnight with 2–4 nM 125I-
Bgtx (specific activity, 200 Ci/mmol) (PerkinElmer) at 20°C in the pres-
ence of 2 mg/ml BSA. Specific radioligand binding was defined as total
binding minus nonspecific binding determined in the presence of 1 M
cold Bgtx (Sigma-Aldrich).
Immunoprecipitation of [3H]epibatidine-labeled receptors by anti-
subunit-specific antibodies. Tissue extracts were preincubated with 2 M
Bgtx, labeled with 2 nM [3H]Epi, and incubated overnight with a saturat-
ing concentration of affinity-purified anti-subunit IgG (20–30 g)
(Sigma-Aldrich). The immunoprecipitation was recovered by incubat-
ing the samples with beads containing bound anti-rabbit goat IgG (Tech-
nogenetics). The level of antibody immunoprecipitation was expressed
as the percentage of [ 3H]Epi-labeled receptors immunoprecipitated by
the antibodies (taking the amount present in the Triton X-100 extract
solution before immunoprecipitation as 100%) or as femtomoles of im-
munoprecipitated receptors/milligram of protein.
Receptor subtype immunopurification. For each purification experi-
ment, the dorsal and ventral striatum from20 to 30 animals was dissected
and immediately frozen at80°C and processed as described by Gotti et
al. (2005a). The extract was incubated three times with 5ml of Sepharose
4B-bound anti-6 antisera (anti-6 CYT) to remove the 6* receptors.
The 6-depleted flow-through fraction was collected for additional pro-
cessing. The bound6* population was eluted from column bymeans of
incubation with 100 M 6 CYT peptide. The flow-through and the
eluted receptors were analyzed by immunoprecipitation using subunit-
specific antibodies, as described above, after labeling with 2 nM [3H]Epi.
Deduction of receptor subtype composition. To obtain a quantitative
evaluation of the subunit composition of a receptor subtype, it is neces-
sary to evaluate the efficiency of immunoprecipitation of antigens by
their respective antisera. For our subunit-specific antisera, we found an
efficiency of immunoprecipitation ranging from75 to 90%.This suggests
that the figures that we obtained in this study are probably slightly un-
derestimated. In addition, in defining nAChR subtypes in striatum and
ventral midbrain, we followed the current hypothesis that heteromeric
nAChRs comprise two subunits bearing the principal amino acid loops
for acetylcholine binding interfaces (i.e., 2, 3, 4, or 6 subunits) and
two subunits bearing the complementary amino acid loops for acetylcho-
line binding interfaces (i.e., 2 or 4 subunits), whereas the fifth subunit
can be either a complementary subunit, or a principal subunit (3 or 4
subunits), or a purely structural subunit (5 or3 subunits) (Gotti et al.,
2009).
Pharmacological experiments on immunoimmobilized
native subtypes
The affinity-purified anti-3, 6, 2, or 4 antibodies were bound to
microwells (Maxi-Sorp; Nunc) by means of overnight incubation at 4°C
at a concentration of 10g/ml in 50mMphosphate buffer, pH7.5.On the
following day, the wells were washed to remove the excess of unbound
antibodies and then incubated overnight at 4°Cwith 200l of 2%Triton
X-100 superior colliculus, cerebral cortex, or cerebellum membrane ex-
tract containing 5–10 fmol of 125I-Epi binding sites. After incubation, the
wells were washed, and the presence of immobilized receptors revealed
by means of 125I-Epi binding.
For saturation experiments, 125I-Epi was used at concentration rang-
ing from 0.005 to 0.5 nM. For inhibition experiments, the immunoim-
mobilized receptors were incubated [30 min, room temperature (RT)]
with various concentrations of toxins before adding 125I-Epi at the Kd
concentration. Incubation was prolonged overnight at 4°C. Nonspecific
binding was measured in the presence of 100 nM unlabeled Epi.
Pharmacological experiments on HEK cells transfected with
human 32 subtype
HEK cells transiently transfected with 32 human subunits were a gen-
erous gift from Prof. Fabrizio Eusebi (Universita` La Sapienza, Rome,
Italy). Binding to membrane was performed overnight by incubating
aliquots of the cellmembranewith [ 3H]Epi concentrations ranging from
0.005 to 2 nM at 4°C. Nonspecific binding (averaging 5–10% of total
binding) was determined in parallel by means of incubation in the pres-
ence of 100–250 nM unlabeled Epi.
For inhibition experiments, the immunoimmobilized receptors were
incubated (30 min; RT) with various concentrations of toxins before
adding [ 3H]Epi at theKd concentration. At the end of the incubation, the
samples were centrifuged and washed once with 10 sodium phosphate,
pH7.4, plus 50mMNaCl, the pellet was dissolvedwith 2NNaOH, and the
filters were counted in a beta counter.
-Conotoxin MII free fraction in plasma and brain tissue
Equilibriumdialysis: evaluation of plasma and brain tissue binding.Plasma
and brain unbound fractions were determined in a 96-well equilibrium
dialysis apparatus (HTDialysis) using a previously reported method
(Kalvass and Maurer, 2002). In brief, fresh rat plasma and brain tissue
were obtained the day of the study. Membranes (12–14 kDa cutoff),
obtained from Spectrum Laboratories, were conditioned in HPLC water
for 60 min, followed by 20% ethanol for 20 min, and 100 mM sodium
phosphate, pH 7.4, buffer for 15 min.
Brain tissue was diluted twofold with a surrogate buffer for CSF (7.3
g/L NaCl, 186.4 mg/L KCl, 239.9 mg/L MgCl2, 185.2 mg/L CaCl2, and
536.0 mg/L Na2HPO47H2O, pH 7.4), and it was subjected to homoge-
nization using an Autogizer (Tomtec).
CntxMIIwas added to samples of plasma and brain tissue homogenate
(10 g/ml and 10 g/g, respectively), and 150 l aliquots (n  6) were
loaded into the 96-well equilibrium dialysis apparatus and dialyzed
against an equal volume of 100mM sodium phosphate, pH 7.4, buffer for
plasma or against surrogate CSF (see above) for brain tissue homoge-
nates. Equilibrium was achieved by incubating the 96-well equilibrium
dialysis apparatus in a temperature-controlled incubator at 37°C (Elet-
trofor Scientific Instrument) for 5 h, using an orbital shaker at 125 rpm
(Elettrofor Scientific Instrument).
At the end of the incubation period, 50 l aliquots of plasma or brain
homogenate and buffers were transferred to a 96-deep-well plate, and the
composition in each tube was balanced with control fluid, such that the
volume of buffer to brain or plasma was the same. Sample extraction was
performed by the addition of 400l of acetonitrile containing an internal
standard. The samples were vortex-mixed and centrifuged, and the su-
pernatant was analyzed by the HPLC–mass spectrometry (MS)/MS as
described below.
Plasma unbound fractionwas calculated from the ratio of analyte peak
areas determined in buffer versus plasma samples. Equation 1, which
accounts for the effect of tissue dilution on unbound fraction (Kalvass
and Maurer, 2002), was used to calculate the brain unbound fraction as
follows:
fu-undiluted 
1/D
1/fu-diluted  1  1/D	
, (1)
whereD is dilution factor in brain homogenate, and fu-diluted is the mea-
sured free fraction of diluted brain tissue.
Samples analysis. All samples were analyzed by means of HPLC-
MS/MS on a PerkinElmerSciex Instruments API-4000 tandem quadru-
pole mass spectrometer (Applied Biosystems), using a Turbo V Ionspray
operated at a source temperature of 600°C (80 psi of nitrogen). The liquid
chromatography/tandem MS was operated in positive-ion, multiple-
reaction monitoring mode. The parent/daughter ion pair for CntxMII
was 856.0 (double-charged ion)/109.9. Samples (10 l) were injected
using a CTC Analytics HTS Pal autosampler onto a Synergy RP MAX 4
m, 2.0  30 mm column (Phenomenex) at an eluent flow rate of 1.5
ml/min. Analytes were eluted using a high-pressure linear gradient pro-
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gram, by means of an HP1100 binary HPLC system (Agilent Technolo-
gies), using deionized H2O containing 0.1% (v/v) formic acid as solvent
A and acetonitrile containing 0.1% (v/v) formic acid as solvent B. The
gradient was held at 5% solvent B for 0.3min, before increasing to 95% at
1.0 min, remaining at 95% until 1.5 min before returning to the starting
conditions. The cycle time was 1.9 min per sample, and typical run times
ranged from 2.4 to 2.7 min.
Stability. Experiments to assess CntxMII recovery were designed to
evaluate the stability of CntxMII in rat plasma and brain homogenate
samples. CntxMII was added to samples of plasma and brain tissue ho-
mogenate (10g/ml and 10g/g, respectively), and 150l aliquots (n
3) for eachmatrix were immediately processed as previously described at
the end of the incubation period, whereas 150l aliquots (n 3) for each
matrix were incubated over for 5 h at 37°C (see above). At the end of the
incubation period, 50 l aliquots of plasma or brain homogenate were
transferred to a 96-deep-well plate, and the composition in each tubewas
balanced with control fluid, such that the volume of buffer to brain or
plasma was the same.
All samples were vortex-mixed and centrifuged, and the supernatants
were analyzed by the HPLC-MS/MS as described above. For dialysis
sample stability average analyte peak area was compared between solu-
tions of incubated and fresh spiked matrix. This comparison was per-
formed in presence and in absence of protease inhibitors.
Microdialysis procedure
Rats were anesthetized with halothane (see above) and placed in a flat
skull position in a Kopf stereotaxic apparatus. A microdialysis probe
(CMA/12; 2 mm dialysis membrane; 100,000 Da cutoff; CMA/Micro-
dialysis) was inserted through a guide cannula into the right ventral
striatum at the following coordinates from bregma: A, 1.7 mm; L,
0.8 mm; D, 6.0 mm from dura (Ferrari et al., 2002; Paxinos and
Watson, 2007) (supplemental Fig. 1, available at www.jneurosci.org
as supplemental material). In some experiments, in addition to the
cannula in the nAc, a second cannula was inserted in the ipsilateral
VTA at the following coordinates from bregma: A, 5.3 mm; L, 0.8
mm; and D, 6.2 mm from dura (Paxinos and Watson, 2007). The
guide cannulae were permanently secured with dental cement. After
surgery, the rats were placed in a circular Plexiglas cage and allowed to
recover overnight before the microdialysis experiment. One or 2 d
after insertion of the guide cannula, the microdialysis probe was in-
serted into the guide cannula The inlet tubing of the probe was con-
nected to a microinjection pump (CMA/100; CMA/Microdialysis)
and perfused with artificial CSF (aCSF) (2.5 mM KCl, 125 mM NaCl,
1.26mMCaCl2, 1.18mMMgCl2, 2 mMNa2HPO4, pH 7.4) at a flow rate
of 1.1 l/min (22 l/20 min sample).
Detection of dopamine
A20l volume from each sample was injected into anHPLC systemwith
electrochemical detection for determination of DA concentration (ESA
coulometric detector with a 5014 B cell; voltage: E1,150mV; E2,220
mV) (Coulochem II Electrochemical Detector). Separation of DA was
performed on an ESA HR-80 column (80 mm  4.6 mm inner diame-
ter). Themobile phase consisted of 18%methanol in 75mMNaH2PO4, 1
mM 1-octanesulfonic acid (sodium octane sulfonate), and 20 M EDTA,
pH 5.6. The flow rate was 0.8 ml/min (Shimadzu LC-10ADVP, Solvent
DeliveryModule). The chromatograms were integrated using Jasco Bor-
win HPLC software. DA detection limit was 5 fmol/sample.
Habituated locomotion
Animals were deeply anesthetized with halothane (see above), and two
microdialysis probe guide cannulae (see above) were implanted into the
right and left VTA (coordinates frombregma: A,5.3mm; L, 3.0mm;D,
6.3mmfromdura; the cannulaewere insertedwith an angle of 16°) and
secured to the skull with dental cement. One to 3 d after surgery, the
awake animal was gently restrained by the experimenter and a microdi-
alysis probe (see above) was inserted into each guide cannula. The probes
were connected to a microinfusion pump (see above) and continuously
perfused at 1.1 l/min with aCSF.
Locomotor activity was measured in motility cages (Macrolon III;
38 20 16 cm) equipped with a lower row of four infrared beams for
detection of horizontal movements and an upper row of four infrared
beams for vertical movements (MED Associates). Interbeam distance
was 8 cm horizontally and 6 cm vertically, and horizontal activity was
recorded for 2 h in 5 min intervals (MED-PC Software). The animals
were placed into the cages for a 60 min habituation period (Ferrari et al.,
2002) and then perfused through the two dialysis cannulae with cono-
toxin or aCSF. Fifteenminutes after the start of conotoxin perfusion, the
rats were injected with nicotine (0.4 mg/kg, base, i.p.) or vehicle. Habit-
uated locomotion was measured for 60 min after the treatment.
Nicotine self-administration
Subjects. Rats were individually housed in a temperature-controlled en-
vironment (21–23°C) on a 12 h light/dark cycle (60 lx) with light on at
7:00 A.M. Animals were food restricted by 85–90% to maintain their
body weight range between 240 and 260 g (daily checked): rats were fed
ad libitum up to a body weight of 
290–300 g (average weight for 3
consecutive days), and then the 85% of their average body weight was
calculated (
250 g), and their daily diet reduced and maintained stable
(by daily checking body weight) for the rest of the study. Food diet (three
to four pellets, for a total of 15–20 g/d) was made available after each
experimental session. The maximum amount of sucrose pellet intake
during training sessionswas 4.5 g/d for those subjectsmeeting the criteria
(see below, Training to lever press). Animals had ad libitum access to
water except during experimental sessions.
Rats were trained or tested once daily. All animal procedures were
performed in accordance with the Principles of Laboratory Animal Care
(National Institutes of Health Publication No. 85-23, revised 1985), the
European Communities Council Directive of 24 November 1986 (86/
609/EEC). These procedures have been approved by the Interdepart-
mental Centre for Laboratory Animal Service and Research of the
Universita` degli Studi di Verona, according to article 7 D.L. 116/92 of the
Italian legislation. All efforts were made to minimize animal suffering
and to keep the lowest number of animals used.
Apparatus. Behavioral testing was conducted in eight operant cham-
bers (Coulbourn Instruments) encased in sound-insulated cubicles,
equippedwith ventilation fans (UgoBasile). Each chamberwas equipped
with two levers, symmetrically centered on the front panel, and located
12.5 cm apart, 1 cm above the grid floor. The foodmagazine was situated
in an opening in the panel between the two levers, 1 cm above the floor.
This openingwas closed during nicotine self-administration training. A 2
W white house light was located 26 cm above the food magazine and
activated during the entire session duration, except during time-out
(TO) periods. Right lever presses corresponding to fixed-ratio (FR) val-
ues required by the schedule of reinforcement produced the delivery of
45 mg sucrose pellet (Bioserv) or the activation of the infusion pump
(model A-99Z; Razel Scientific Instruments). Nicotine solutions were
administered via the infusion pump at a volume of 0.027 ml during a 1 s
period. Sucrose pellet delivery was signaled by the 1 s illumination of a 4
Wwhite stimulus light located in the samehole of the foodmagazine only
during the training for lever press. During self-administration sessions,
reinforcer delivery (nicotine infusion or sucrose pellet) was signaled by
1 s turn-on of one yellow and one green light-emitting diode centrally
placed above the food magazine. Left lever presses (“inactive lever
presses”) did not have any consequence. All types of lever presses, sucrose
pellet and infusion deliveries were recorded. Lever presses were also re-
corded during TO periods. Data acquisition and schedule parameters
were controlled by a Med-PC software (MED Associates) running on a
PC computer interfaced with the chambers via interface modules (MED
Associates).
Training to lever press. After a 24 h food deprivation period, rats were
trained to lever press for food as a reinforcer. The final training schedule
of reinforcementwas a FR2, session duration up to 60min.Once subjects
met the criteria of at least 25 reinforcers/1 h session (it required between
6 and 10 daily sessions), rats underwent surgery.
Surgery.Rats were anesthetizedwith 0.5mg  kg1  0.5ml1medeto-
midine (Domitor; Pfizer), 10 mg/kg tiletamine plus 10mg/kg zolazepam
(Zoletil 100; Virbac; 0.2 ml/kg, i.m.), and then implanted with (1) a
silicon catheter (inner diameter, 0.30 mm; outer diameter, 0.63 mm;
Cam Caths) in the right jugular vein, and (2) two microdialysis guide
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cannulae (see above) bilaterally into the right and left VTA (coordinates
from bregma: A, 5.3 mm; L, 3.0 mm; D, 6.3 mm from dura; the
cannulae were inserted with an angle of 16°) and secured to the skull with
dental cement. Immediately after surgery, animals weremedicatedwith 5
mg  kg1  1 ml1 subcutaneous carprophene (Rimadyl; Pfizer) and
25,000,000 IU of benzylpenicilline plus 1 g/kg dihydrostreptomycin
(Rubrocillina Forte; Intervet; 1 ml/kg, s.c.), 0.5 mg  kg1  0.1 ml1
intramuscular atipamezole (Antisedan; Pfizer). Each day after recovery,
animals received 0.1 ml of one intravenous injection of heparin solution
(30 IU/ml heparin sodium; Sigma-Aldrich) before and after the experi-
mental session to check catheter patency. In case of no in or out flushing,
catheter patency was assessed by loss of righting reflex induced by pen-
tobarbitone sodium (50 mg/kg) intravenous infusion through the cath-
eter. Rats not responding to pentobarbitone were removed from the
study.
Training in the nicotine self-administration procedure. This procedure
has been described previously (Chiamulera et al., 2010). After the period
of recovery, rats were trained to intravenously self-administer nicotine
(FR1: nicotine, 0.03 mg  kg1  infusion1; TO, 60 s; session duration
up to 25 infusions were delivered or 3 h elapsed, no priming injection).
Adjustment of nicotine concentration to changes in rat body weight was
not needed since rat body weight was kept stable at 250 g (10 g). Lever
pressing during theTOperiodwas also recorded, although it did not have
any consequence. If the animals met the criterion of 25 infusions within
the end of the daily session, the FR valuewas increased to FR2 and then to
FR3 with session duration lasting up to 1 h.
Rats were considered to reach a stable responding on nicotine self-
administration under a FR3 schedule of reinforcement when the value
of reinforcers/session did not vary 20% between three consecutive
sessions.
CntxMII treatment.On test day, two microdialysis probes (see above)
were inserted into the VTA guide cannulae. Then, rats were placed in a
plastic bowl and external tips of the probes were connected to an inlet
tubing coming from a microinfusion pump (see above) that delivered
first aCSF for 30 min and, then, 10 M CntxMII in aCSF, or aCSF
alone (control) for 15 min, at a flow rate of 1.1 l/min. Immediately
after, rats were placed in Skinner box and underwent nicotine self-
administration session with a schedule of reinforcement, FR3: 0.03
mg  kg1  infusion1 nicotine; TO, 60 s; 1 h session.
Each rat received both treatments (CntxMII or aCSF) in a balanced
order on different daily sessions (test sessions) with at least three daily
sessions elapsing (baseline sessions) to assess stability of responding.
Food-maintained responding
Rats allocated to food-maintained responding test were initially trained
to lever press for food (similarly to rats undergoing nicotine self-
administration experiments) (see above, Training for lever press) and
then exposed to a slightly different FR2 schedule for food reinforcement:
FR2, TO, 60 s period; session duration, up to 60 min. At stable perfor-
mance of responding for food reinforcement (values did not vary20%
between three consecutive sessions), FR value was increased to FR3.
Stable responding for food on FR3 schedule was reached after 11.7
4.8 sessions (mean SD). At stability, the average number of food rein-
forcers/session was 54.8  0.8. Rate of responding was 346.6  52.1
active lever presses and 4.5 1.9 inactive lever presses (means SEM of
the last three food-responding sessions before starting the testing phase;
data only from rats with correct VTA guide cannulae placements; n 6).
Determination of probe location in in vivo procedures
At the end of microdialysis, locomotion, or self-administration experi-
ments, the animal was killed with a lethal injection of pentobarbital (65
mg/kg, i.p.), its brain was removed from the skull, and the position of the
microdialysis probes was verified by visual inspection of the fresh tissue
or the frozen brain during cut at the cryostat. The probe track was visible
as a small hemorrhagic line. Data from brains with large hemorrhages
(2 mm in diameter) or misplaced probe(s) location were discarded. In
an average experiment with 15 animals (control plus treatment), we had
one to two rats discarded because of a large hemorrhage and two rats
discarded because of probemisplacement (supplemental Fig. 1, available
at www.jneurosci.org as supplemental material).
Statistical analysis
The experimental data obtained from the saturation binding experi-
ments performedon immunoimmobilized62*,42*, or34* sub-
types or membrane-bound 32 subtype were analyzed by means of a
nonlinear least-square procedure using the LIGAND program as described
by Munson and Rodbard (1980). The calculated binding parameters were
obtained by simultaneously fitting three independent experiments. The se-
lectionof the best fitting (i.e., one-site versus two-sitemodel) and evaluation
of the statistical significance of the parameters (i.e., comparison of the bind-
ingparameters of the twogroups)werebasedon theF test for the “extra sum
of square” principle. A value of p 0.05 was considered statistically signifi-
cant (Munson andRodbard, 1980). TheKi values of the toxins on Epi bind-
ing were determined by means of the LIGAND program using the data
obtained from three independent experiments and compared by means of
the F test as described above.
DA perfusate levels after nicotine administration were expressed as
percentage of the last three basal values. Differences in treatment groups
were then analyzed by repeated-measures ANOVA (time as within factor
and treatment as between factor) (statistical package, SPSS, version 12).
When a significant treatment effect was observed, the data were further
analyzed with Bonferroni’s or Dunnett’s test for multiple comparisons.
Number of beam breaks in habituated locomotion experiments was an-
alyzed with the same statistical approach.
Since each rat received both treatments, the effects of CntxMII or aCSF
pretreatment on nicotine self-administration and food-maintained re-
sponding were assessed by paired sample Student’s t test comparing dif-
ferences (test session respective baseline session) in the CntxMII and
aCSF tests for each rat (statistical package, SPSS, version 12).
For all analyses, p 0.05 was considered to be the threshold for statis-
tical significance.
Results
nAChR composition in dorsal and ventral striatum,
and ventral midbrain
In a previous paper (Zoli et al., 2002), we determined nAChR sub-
unit composition of DA and non-DA neurons in homogenates of
total striatum. Our aim here is to distinguish nAChRs of the nigro-
striatal [dorsal striatum (i.e., CPu)] and mesolimbic [ventral stria-
tum (i.e., mainly nAc and tuberculum olfactorium)] pathways.
nAChR subunits expressed in DA neurons of dorsal
and ventral striatum
We first determined the overall composition of nAChRs ex-
pressed by different neuronal populations by studying [3H]Epi-
labeled receptor immunoprecipitation by subunit-specific
antisera. We studied control, intact, animals, animals lesioned
with the DA neuron-selective toxin 6OHDA, and animals with
bilateral eye enucleation. 6OHDAcaused an almost complete loss
of DA cell structures as shown by a90% decrease in [3H]WIN
35,428 binding (data not shown). Since the retina is a major
source of nAChR subtypes with uncommon neuronal subunits
(such as 2, 3, 5, 6, and 3) (Moretti et al., 2004; Gotti et al.,
2005b; Cox et al., 2008), we performed bilateral eye enucleation
to assess a possible contribution of these minor subtypes from
visual afferents. A thirdmajor source of 6* nAChRs in the brain
is the locus ceruleus, where high levels of 6 mRNA have been
detected (LeNove`re et al., 1996). However, in preliminary exper-
iments, we showed that lesion of the noradrenergic pathway with
the selective toxin DSP-4 does not alter [3H]Epi binding in the
dorsal or ventral striatum, or ventral midbrain (supplemental
Fig. 2, available at www.jneurosci.org as supplemental material).
Although the concentration of [3H]Epi-labeled receptors was
much higher in dorsal (172  11 fmol/mg protein) (data not
shown) than in ventral striatum (94 8 fmol/mg protein) (data
not shown), the overall nAChR subunit composition was re-
markably similar in the two regions (Fig. 1A,B). Bilateral eye
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enucleation did not significantly alter nAChR subunit concentra-
tion in the two regions. 6OHDA significantly decreased 4 and
2 subunit levels and caused an almost complete loss of 5, 6,
and 3 subunits in both regions. Although the same pattern of
subunit decrease was observed in the two regions, the deduced
subtype composition in DA neurons showed some interesting
heterogeneity between dorsal and ventral striatum (Table 1) (for
rules and caveats to be used in deductions about nAChR compo-
sition starting from immunoprecipitation experiments, see Ma-
terials andMethods). In dorsal striatum,
90%of the overall6*
nAChRpopulation also contained4 subunit, presumably form-
ing a receptor with an 62 binding interface and an 42 bind-
ing interface, whereas in the ventral striatum only 40% of the
overall 6* nAChR population contained 4 subunit. Therefore,
in the ventral striatum, 
60% of 6* nAChRs have two 62
binding interfaces.
Previous immunopurification experiments in extracts of total
striatum (Zoli et al., 2002) showed that 5 subunit is associated
with 4* nAChRs, whereas 3 subunit is associated with 6*
nAChRs. This picture is coherent with present data as regards
ventral striatum, where the concentration of [3H]Epi receptors
immunoprecipitated by 6 and 3 subunit antibodies is very
similar (6, 11.1 fmol/mg protein; 3, 11.5 fmol/mg protein).
However, in the dorsal striatum, the amount of 3* nAChRs is
larger than that of 6* nAChRs (6, 26.4 fmol/mg protein; 3,
31.4 fmol/mg protein) (Fig. 1A). Therefore, we hypothesize the
presence of a minor population (
6% of total nAChRs) of
432 receptors selectively present in DA terminals of the CPu
(Table 1).
We also studied 125I-Bgtx binding (a marker of 7* nAChRs)
in dorsal and ventral striatum and ventral midbrain, and found
no significant difference between 6OHDA or eye-enucleated rats
and control rats in any region examined (supplemental Fig. 3,
available at www.jneurosci.org as supplemental material).
6* and non-6* nAChRs expressed in dorsal
and ventral striatum
To confirm this subtype heterogeneity, we performed immu-
nopurification experiments using an affinity column bearing
Figure1. A–C, ImmunoprecipitationofnAChRsubunitsin2%TritonX-100extractsofdorsal striatum
(A), ventral striatum (B), or ventral midbrain (C) from control rats and rats that underwent bilateral
eyeenucleationorbilateral injectionof6OHDAintothemedialforebrainbundle.Eachvaluerepresents
themean SEM of five to nine separate determinations performed in triplicate. Statistical analysis
was according to one-way ANOVA followed by Bonferroni’s test. **p 0.01, *p 0.05 versus eye
enucleation; ##p0.01, #p0.05, 0.10p0.05versus control (ctrl). A,2: F(2,16)0.29,
NS;3: F(2,16) 1.10, NS;4: F(2,16) 70.46, p 0.001; 6OHDA versus eye, p 0.001; 6OHDA
versus control, p 0.001;5: F(2,16) 8.43, p 0.003; 6OHDA versus eye, p 0.010; 6OHDA
versus ctrl,p0.006;6: F(2,16)18.47,p0.001; 6OHDAversus eye,p0.001; 6OHDAversus
ctrl,p0.001;2:F(2,16)8.69,p0.003;6OHDAversuseye,p0.008;6OHDAversusctrl,p
0.006;3:F(2,16)14.37,p0.001;6OHDAversuseye,p0.001;6OHDAversusctrl,p0.001;4:
F(2,16)0.01,NS.B,2: F(2,17)0.99,NS;3: F(2,17)0.87,NS;4: F(2,17)57.47,p0.001;
6OHDAversuseye,p0.001;6OHDAversusctrl,p0.001;5:F(2,17)18.05,p0.001;6OHDA
versus eye,p0.001; 6OHDAversus ctrl,p0.001;6: F(2,17)22.03,p0.001; 6OHDAversus
eye, p 0.001; 6OHDA versus ctrl, p 0.001;2: F(2,17) 42.27, p 0.001; 6OHDA versus eye,
p 0.001; 6OHDA versus ctrl, p 0.001;3: F(2,17) 22.08, p 0.001; 6OHDA versus eye, p
0.001; 6OHDA versus ctrl, p 0.001;4: F(2,17) 0.75, NS. C,2: F(2,20) 9.84, p 0.001; eye
versus ctrl, NS; 6OHDA versus eye, p 0.037; 6OHDA versus ctrl, p 0.001;3: F(2,19) 2.20, NS;
4: F(2,16) 49.94, p 0.001; eye versus ctrl, NS; 6OHDA versus eye, p 0.001; 6OHDA versus
4
ctrl, p 0.001; 5: F(2,15) 15.03, p 0.001; eye versus ctrl, NS; 6OHDA versus eye, p
0.003; 6OHDA versus ctrl, p 0.001; 6: F(2,15) 24.97, p 0.001; eye versus ctrl, p
0.069; 6OHDA versus eye, p 0.001; 6OHDA versus ctrl, p 0.001; 2: F(2,15) 32.81,
p  0.001; eye versus ctrl, NS; 6OHDA versus eye, p  0.001; 6OHDA versus ctrl, p 
0.001;3: F(2,12) 39.49, p 0.001; eye versus ctrl, p 0.013; 6OHDA versus eye, p
0.001; 6OHDA versus ctrl, p 0.001; 4: F(2,18) 3.87, p 0.040; eye versus ctrl, NS;
6OHDA versus eye, NS; 6OHDA versus ctrl, p 0.037.
Table 1. Composition of nAChR subtypes expressed by DA neurons of dorsal and
ventral striatum and ventral midbrain as deduced from immunoprecipitation
experiments
% of total2* nAChRs (% of6* nAChRs)
nAChR subtype Dorsal striatum Ventral striatum Ventral midbrain
42 20.5 11.3 29.8
242 0 0 8.0
452 39.5 53.4 32.2
423 6.4 1.1 8.6
4623 29.9 (89.0) 13.7 (40.0) 21.4 (100.0)
623 3.7 (11.0) 20.5 (60.0) 0 (0)
4* 96.3 79.5 100.0
4 (non-6)* 66.4 65.8 78.6
6* 33.6 34.2 21.4
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anti-6 antibody. Although quantitation with this method is
less accurate because of the addition of additional steps in the
procedure than quantitation obtained with immunoprecipita-
tion, immunopurification experiments give a direct demonstra-
tion of the presence of a subunit in a receptor population.
Selective 6* nAChR immunodepletion was confirmed by the
fact that immunoprecipitated6-containing [3H]Epi-labeled re-
ceptors decreased from 15.4 1.5 and 12.9 2.4% to 1.3 1.1
and 2.0 1.4% in the flow-throughof the6 column fromdorsal
and ventral striatal extract, respectively. As shown in Figure 2A,
in the dorsal striatum all receptors immunopurified on the 6
column (6* nAChRs) had 4 subunit, whereas in the ventral
striatum 75% of 6* receptors contained an 4 subunit. This
significant difference in the content of 4 subunit in 6* immu-
nopurified receptors tallies well with the findings of immunopre-
cipitation experiments and confirms the existence of a substantial
population of 6(non-4)* nAChRs in the ventral, but not dor-
sal, striatum.
As regards the analysis of the flow-through from 6 columns,
the only significant difference between dorsal and ventral stria-
tum was a higher content of 3 subunit in the dorsal striatum
(Fig. 2B). Also, these results tally well with the immunoprecipi-
tation findings and confirm the existence of a minor population
of 4(non-6)32 nAChRs in the dorsal striatum that is mar-
ginally, or not, represented in the ventral striatum.
nAChR subunits expressed in DA neurons of ventral midbrain
We made an attempt to determine what nAChR subtypes are
expressed in DA cell bodies and dendrites of the ventral mid-
brain. Because of the relatively little amount of nAChRs that can
be recovered from this region, we sampled homogenates of the
entire ventral midbrain (without interpeduncular nucleus) (see
Materials and Methods) and could not distinguish between the
neurons of origin of the nigrostriatal pathway (substantia nigra)
and those of the mesolimbic pathway (VTA).
A significant decrease and a trend for a significant decrease,
respectively, were detected in the levels of 3 and 6 nAChR
subunits in rats that underwent bilateral eye enucleation (Fig.
1C). This finding tallies well with the evidence of very high levels
of CntxMII binding in the medial terminal nucleus of the acces-
sory optic tract (MT) (Mugnaini et al., 2006). 6OHDA-induced
DA neuron degeneration markedly decreased 4, 2, and 3
subunit levels and caused an almost complete loss of 2, 5, and
6 subunits (Fig. 1C). This pattern differs from what has been
observed in DA terminals of both dorsal and ventral striatum as
regards 2 and 3 subunits (see above). In fact, 2 decrease in
6OHDA-treated rats was observed only in the ventral midbrain.
Indeed, differently from striatal levels, DA denervation caused
only a partial loss of 3 subunit in the ventral midbrain implying
that in this region there exists a substantial population of 3*
nAChRs not expressed by DA neurons. Very likely, non-DAergic
3 subunit is associated with 34* nAChRs expressed in the
fasciculus retroflexus that crosses the ventral midbrain, as re-
cently shown in immunoprecipitation experiments (Grady et al.,
2009).
The composition of nAChR subtypes expressed by DA neu-
rons in the ventral midbrain deduced from present immunopre-
cipitation experiment is reported in Table 1.
nAChR subtype selectivity of conotoxins
Immunoprecipitation and immunopurification studies de-
scribed above confirm and further refine the notion that 62*
nAChRs constitute a major receptor population expressed by
both cell body/dendrite compartment and nerve terminal com-
partment of the nigrostriatal and mesolimbic DA pathways. To
characterize the contribution of these receptors to the neuro-
chemical and behavioral effects of systemic nicotine, we decided to
use 62*-selective antagonists, namely CntxMII, CntxMIImod
(an analog ofCntxMII thatwas reported to have higher selectivity
for62* receptors) (McIntosh et al., 2004), andCntxPIA, in the
awake freely moving animals. We first determined the affinity of
these toxins for 62* and other nAChR subtypes expressed in
the rat ventral midbrain and striatum.
62* nAChRs immunopurified from rat superior
colliculus membranes
Saturation binding analysis revealed an affinity for 125I-Epi bind-
ing of 38 pM (Table 2). CntxMII competition binding studies
were performed, and, in agreement with previously reported data
(Champtiaux et al., 2003; Gotti et al., 2005b), we found that the
62* nAChRs have a statistically significant better fit for a two
site model with high [Ki of 3 nM; coefficient of variation (CV),
39%] and low affinity (Ki 10 M; CV, 41%) for CntxMII (Fig.
3, Table 2). The high- and low-affinity sites are thought to corre-
spond to binding at 62 and 42 interfaces, respectively (Zoli
et al., 2002; Champtiaux et al., 2003; Gotti et al., 2005a). The
CntxMIImod showed a single site presumably for the 62 sub-
type with relatively low affinity (Ki of 1.8 M; CV, 57%). The
CntxPIA also showed a statistically significant better fit for a two-
Figure2. A,B, Immunoprecipitation analysis of the subunit content of6* (A) andnon6*
(B) nAChR subtypes immunopurified through affinity column from striatal extracts and labeled
with 2 nM [ 3H]Epi. The results are expressed as percentage of total [ 3H]Epi binding immuno-
precipitatedby2antibody. Eachdatapoint is themeanSEMof three to fivedeterminations
performed in triplicate. Statistical analysis was according to independent-sample Student’s t
test; **p 0.01. A,4: df 10, t 3.21, p 0.009. B,3: df 16, t 4.51, p 0.001.
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site model with high- (Ki of 37 nM; CV,
59%) and low-affinity (Ki 10 M) sites.
32* nAChRs immunopurified from rat
superior colliculus and HEK cells
Immunoimmobilized32*nAChRs from
superior colliculus proved to have a too low
concentration to be used in competition
experiments. Therefore, the analysis of
32* nAChRs was performed on recep-
tors purified from HEK cells transfected
with human 3 and 2 subunit. Satura-
tion binding analysis revealed an affinity
for 125I-Epi binding of 35 pM (Table 2).
When tested on the membrane-bound
32 receptors, the CntxMII showed an
affinity of 55 nM (CV, 37%), which is sim-
ilar to the value of 115 nM previously de-
tected with immunopurified 32* nAChRs from rat superior
colliculus (Gotti et al., 2005b). Both the CntxMIImod and Cntx-
PIA showed a very low affinity for this subtype with Ki values of
10 and 11 M, respectively (Fig. 3).
42* and 34* nAChRs immunopurified from rat cerebral
cortex and cerebellum, respectively
Saturation binding analysis revealed an affinity for 125I-Epi bind-
ing of 33 and 98 pM for 42* and 34* receptors, respectively.
All three toxins showed a very low affinity (10 M) toward the
42* or 34* subtypes (Table 2).
On the basis of these results, we confirmed that CntxMII has
high affinity for both 62* and 32* subtypes, whereas Cntx-
PIA only has high affinity for the 62* subtype. Instead, our
batch of CntxMIImod did not show high affinity for native 62
interface and was not used in the following experiments.
Setup of the method for the intracerebral perfusion
of conotoxins
Since conotoxins, being peptidic molecules, cannot cross the
blood–brain barrier (Blanchfield et al., 2007), we thought to ad-
minister them intracerebrally via perfusion through a microdi-
alysis cannula. In a set of preliminary experiments, we studied
CntxMII availability in brain tissue after perfusion through a
microdialysis cannula with a large (100,000 Da) cutoff. With this
aim, we determined the diffusion of 125I-CntxMII from amicro-
dialysis cannula into the brain (Fig. 4), the free (unbound) con-
centration ofCntxMII in brain tissue (Table 3), and the biological
efficacy of CntxMII locally perfused at the concentration of 10
M (supplemental Fig. 4, available at www.jneurosci.org as sup-
plemental material).
To assess the intracerebral diffusion of CntxMII after perfu-
sion of the toxin through a microdialysis cannula, we perfused
125I-CntxMII (2000 Ci/mmol, 10M dissolved in aCSF) through
a microdialysis probe (100,000 Da cutoff) located in the VTA,
followed by killing of the animal after 5, 15, or 60 min of perfu-
sion and autoradiographical detection of the labeled toxin. The
results are shown in Figure 4. The central part of the labeled area
corresponds to the trace of the cannula and has a high concen-
tration of radioactivity, corresponding to 500–600 nM 125I-
CntxMII. This is 
5% of the concentration of CntxMII present
in the solution perfused through the cannula. Decrease of labeled
toxin from the site of probe location follows an exponential de-
cay. The concentration of radioactive CntxMII at 1 mm far from
the cannula drops to 18, 82, and 105 nM after 5, 15, and 60min of
perfusion, respectively.
Brain tissue binding experiments, using equilibrium dialysis
methodology, showed that only a limited (10%) fraction of
CntxMII in a brain homogenate is unbound and therefore avail-
able for binding to target receptors (Table 3) (for additional de-
tails, see supplemental material, available at www.jneurosci.org
as supplemental material).
From these experiments, we can derive that a reasonable esti-
mate of the effective concentration of CntxMII perfused into the
brain from a dialysis probe varies between 0.5 and 0.1% of the
Figure 3. Inhibition of 125I-Epi binding to immunoimmobilized62* and32* nAChRs by CntxMII [H9A, L15A] (CntxMIImod),
and CntxPIA. The curveswere obtained by fitting three to four separate experiments using the LIGANDprogram. Error bars indicate SEM.
Figure 4. Intra-VTA diffusion of 125I-CntxMII perfused through amicrodialysis cannula. The
figure shows the levels of 125I-CntxMII concentration at different distances from the probe after
5, 15, or 60min perfusion of 10M 125I-CntxMII. The values are themeanof three experiments.
Table 2. Binding of conotoxins to purified nAChR subtypes
Kd for
125I-epibatidine Ki (CV) for-conotoxin MII Ki (CV) for-conotoxin MII H9A,L15A	 Ki (CV) for-conotoxin PIA
62* purified from superior colliculus 38 pM 3 nM (39%) and10M 1.8M (57%) 37 nM (59%)
32* purified from HEK cells 35 pM 55 nM (59%)a 10M 10M
42* purified from cerebral cortex 33 pM 10M 10M 10M
34* purified from cerebellum 98 pM 10M 10M 10M
aThe Ki value of CntxMII was found to be 115 nM for32* nAChRs immunopurified from rat superior colliculus (Gotti et al., 2005b).
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perfused concentration within a distance of 1 mm far from the
dialysis membrane.
Effects of intra-nAc or intra-VTA perfusion of conotoxins on
systemic nicotine-elicited DA release in the nAc
Effects of intra-nAc or intra-VTA perfusion of CntxMII
We first tested the effects of CntxMII perfusion into the nAc or
the VTA on DA perfusate levels from the nAc. With this aim, we
performed double-probe microdialysis experiments (Zanetti et
al., 2007), placing a probe in the shell subregion of the nAc forDA
detection and another probe in the anterior VTA. To test the
effects of intra-nAcCntxMII administration, CntxMIIwas perfused
through the microdialysis cannula in the nAc, whereas aCSF was
infused into theVTA.To test theeffectsof intra-VTAadministration
of CntxMII, CntxMII was perfused through the intra-VTA probe,
whereas aCSF was perfused into the nAc. The dose of CntxMII (10
M) was selected on the basis of preliminary experiments (see
above). Inboth intra-nAcand intra-VTAexperiments,CntxMIIwas
perfused 15 min before a systemic administration of nicotine (0.4
mg/kg, i.p., nicotine base) (Ferrari et al., 2002).
Peripheral nicotine injection was able to significantly increase
by 
55% DA perfusate levels in the medial nAc (n  7 rats).
Although local perfusion of CntxMII in the nAc did not cause a
significant change in nicotine-elicited increase in DA levels (n
6 rats), local perfusion in the VTA completely abolished DA in-
crease in the nAc (n 5 rats) (repeated-measures ANOVA, time:
F(1,15) 64.43, p 0.001; groups: F(2,15) 5.7, p 0.014; time by
groups: F(2,15)  9.63, p  0.002; post hoc Dunnett’s test:
NicCntxMII-VTA vs NicaCSF, p  0.008; NicCntxMII-
nAc vs NicaCSF, NS) (Fig. 5).
Lack of effect of intra-nAc perfusion of CntxMII was confirmed
in an independent experiment using 1 or 10 M doses (Fig. 6).
CntxMII (1 or 10M)or aCSFwere perfused into thenAc through a
microdialysis probe starting 15 min before systemic nicotine (0.4
mg/kg, i.p., nicotine base) administration. No significant difference
between CntxMII (1 M) (n 4), CntxMII (10 M) (n 5), and
aCSF (n10)perfusionwasdetected (repeated-measuresANOVA,
time:F(5,16)5.42,p0.001; groups:F(2,16)0.03,p0.997; time
by groups: F(10,16) 1.50, p 0.154) (Fig. 6).
We, therefore, focused our subsequent analysis on nAChRs
expressed in the VTA. This is in accordance with a previous paper
(Nisell et al., 1994) showing that intra-VTA but not intra-nAc
infusion of the nonselective antagonist mecamylamine decreased
nicotine-elicited DA release in nAc.We do not, however, exclude
that additional analysis of CntxMII-sensitive nAChRs of the nAc
using different experimental paradigms would evidence their
contribution to the effects of systemic nicotine on DA release in
nAc, as suggested by several lines of evidence obtained in ex vivo
preparations (Grady et al., 2007; Exley et al., 2008). It is possible
that, with the present experimental approach, nAChRs expressed
by nAc DA terminals outside of the access region of the CntxMII
diffusing from the microdialysis cannula were not inhibited, so
that DA continued to be released by the systemic nicotine. This
released DA might reach the microdialysis probe, such that the
intra-nAc CntxMII would appear to be ineffective. Indeed, our
data on local perfusion of CntxMII plus nicotine (supplemental
Fig. 4, available at www.jneurosci.org as supplemental material)
indicate that CntxMII-sensitive receptors of the nAc can be acti-
vated by nicotine also in vivo. Finally, a very recent paper showed
that infusion of CntxMII into the nAc shell was able to decrease
nicotine self-administration (Brunzell et al., 2010).
Effects of intra-VTA perfusion of CntxMII: dose–response study
We then decided to explore in more detail the intra-VTA effects
of CntxMII. The effects on systemic nicotine-elicited release of
DA by three more doses of CntxMII (1M, 100 nM, and 10 nM)
Table 3. Conotoxin MII rat plasma protein and brain tissue binding determined at
10g/ml and 10g/g, respectively, after 5 h incubation on a 96-well equilibrium
dialysis plate (HTDialysis)
Matrix
(Lister hooded rats)
fu%
Brain Plasma
Values 7.09 49.61
5.92 57.35
9.13 56.96
9.71 55.45
7.79 49.83
7.57 47.58
Mean 7.87 50
SD 1.38 NM
Median 7.68 50
Range 5.92–9.71	 47.58 to50	
Abbreviations: fu, Fraction unbound; NM, not measurable.
Figure 5. Effects of intra-nAc or intra-VTA perfusion of 10M CntxMII (15 min before nico-
tine administration) on perfusate DA levels in nAc elicited by nicotine (0.4 mg/kg base, i.p.).
Mean SEM values are expressed as percentage of the last three baseline values before nico-
tine injection. Statistical analysis was according to repeated-measures ANOVA; **p 0.01
versus NicaCSF. Group size: aCSF, seven rats; CntxMII-nAc, six rats; CntxMII-VTA, five rats.
Figure 6. Effects of intra-nAc perfusion of CntxMII (1 or 10M) on DA dialysate levels from
the nAc. Mean SEM values are expressed as percentage of the last three baseline values
before nicotine injection. Statistical analysis was according to repeated-measures ANOVA. No
significant group effect was detected. Group size: aCSF, 10 rats; CntxMII (1M), 4 rats; CntxMII
(10M), 5 rats.
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perfused into the VTA were tested in the double-probe micro-
dialysis paradigm described above. Whereas 100 and 10 nM
CntxMII did not significantly differ from aCSF, DA perfusate
levels in the nAc in rats perfused with 1 M CntxMII into the
VTA significantly differed from vehicle as well as from 100 or 10
nM CntxMII-perfused rats [repeated-measures ANOVA, time:
F(5,24) 6.57, p 0.001; groups: F(3,24) 6.23, p 0.003; time by
groups: F(15,24) 0.79, NS; post hocDunnett’s test vs NicaCSF:
NicCntxMII (1 M), p  0.003; NicCntxMII (100 nM), NS;
NicCntxMII (10 nM), NS] (Fig. 7A).
Effects of intra-VTA perfusion of CntxPIA
To confirm CntxMII effects and refine the subtype selectivity of
the effect, we tested two doses of CntxPIA (100 and 10M) in the
double-probe paradigm. As shown above, this toxin has lower
affinity than CntxMII for 62* nAChRs but higher selectivity
with respect to 32* nAChRs (Table 2). Both CntxPIA doses
blocked nicotine-elicited increase in DA perfusate levels in the
nAc (Fig. 7B), indicating that the effect is attributable to blockade
of62 receptors in theVTA [repeated-measures ANOVA, time:
F(5,15) 2.57, p 0.033; groups: F(2,15) 13.88, p 0.001; time
by groups: F(10,15)  1.47, NS; post hoc Dunnett’s test vs
NicaCSF: NicCntxPIA (10 M), p  0.004; NicCntxPIA
(100 M), p 0.001].
Effects of intra-VTA perfusion of conotoxins on systemic
nicotine-elicited habituated locomotion
Effects of CntxMII and CntxPIA perfused into the VTA
In this paradigm, conotoxins were perfused into the VTA
through bilateral microdialysis cannulae. At both 10 and 1 M
doses, CntxMII perfused starting 15 min before nicotine injec-
tion was able to markedly decrease the increased locomotor ac-
tivity elicited by an intraperitoneal injection of nicotine (0.4 mg/
kg, base, i.p.), whereas CntxMII 100 nM was ineffective [repeated-
measuresone-wayANOVA,F(4,22)8.75,p0.001;Dunnett’spost
hoc test vs NicaCSF: NicCntxMII (100 nM), NS; NicCntxMII
(1M), p 0.015; NicCntxMII (10M), p 0.013] (Fig. 8A). At
10 M dose, CntxPIA was able to markedly decrease nicotine stim-
ulation of locomotion, whereas CntxPIA at 1 M was ineffective
[repeated-measures one-way ANOVA, F(3,18)  6.95, p  0.003;
Dunnett’s post hoc test vs NicaCSF: NicCntxPIA (1 M), NS;
NicCntxPIA (10M), p 0.044] (Fig. 8B).
As a test for possible nonspecific effects of CntxMII on loco-
motion, we studied the effects of intra-VTACntxMII on novelty-
elicited locomotion. CntxMII (1 or 10 M) or aCSF were
bilaterally perfused into the VTA for 15min throughmicrodialy-
sis probes as described above, starting 15 min before placing the
rat in an activity cage. Novelty-elicited locomotionwasmeasured
during the following 60 min. No significant difference between
CntxMII (1 M, n 6; 10 M, n 5) and aCSF (n 14) intra-
Figure 7. A, B, Effects of intra-VTA perfusion (15 min before nicotine administration) of
different concentrations of CntxMII (A) or CntxPIA (B) on perfusate DA levels in nAc elicited by
nicotine (0.4 mg/kg base, i.p.). Mean SEM values are expressed as percentage of the last
three baseline values before nicotine injection. Statistical analysis was according to repeated-
measures ANOVA.A, **p0.01 versus aCSF. Group size: aCSF, six rats; CntxMII (10 nM), six rats;
CntxMII (100 nM), eight rats; CntxMII (1M), eight rats; CntxMII (10M), five rats. B, **p
0.01 versus aCSF. Group size: aCSF, four rats; CntxPIA (10M), five rats; Cntx-PIA (100M), nine
rats.
Figure 8. A, B, Effects of intra-VTA perfusion (15 min before nicotine administration) of
different concentrations of CntxMII (A) or CntxPIA (B) on habituated locomotion elicited by
nicotine (0.4 mg/kg base, i.p.). Mean values are shown. Error bars indicate SEM. Statistical
analysis was according to repeated-measures ANOVA. A, *p 0.05 versus NicaCSF. Group
size: Saline, five rats; aCSF, six rats; CntxMII (100 nM), five rats; CntxMII (1M), five rats; CntxMII
(10M), six rats. B, *p 0.05 versus NicaCSF. Group size: Saline, five rats; aCSF, seven rats;
CntxPIA (1M), six rats; CntxPIA (10M), four rats.
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VTA perfusion was detected (repeated-measures ANOVA, time:
F(5,22) 13.38, p 0.001; groups: F(2,22) 0.30, p 0.741; time
by groups: F(10,22) 0.98, p 0.462) (Fig. 9).
Effects of different delays between intra-VTA CntxMII perfusion
and systemic nicotine administration
As described above, 10 M CntxMII perfused into the VTA
through bilateral cannulae was able to markedly but not com-
pletely inhibit nicotine stimulating action on habituated locomo-
tion. A possible explanation for this partial effect is that CntxMII
did not have sufficient time to diffuse into the VTA and reach all
the relevant molecular targets. We, therefore, tested several de-
lays, 0, 1, or 4 h, between 15min CntxMII (10M) perfusion and
nicotine intraperitoneal injection. As shown in Figure 10, rats
challenged with systemic nicotine immediately after or 1 h after
intra-VTA CntxMII perfusion showed a partial or complete
block of nicotine-elicited habituated locomotion, respectively.
Instead, a 4 h delay led to an almost complete recovery of nicotine
effect [repeated-measures one-way ANOVA, F(3,30)  9.91, p 
0.001; Dunnett’s post hoc test vsNicaCSF:NicCntxMII (0 de-
lay), p  0.043; NicCntxMII (1 h delay), p  0.001;
NicCntxMII (4 h delay), NS].
Effects of intra-VTA perfusion of CntxMII on intravenous
nicotine self-administration
Stable responding for nicotine self-administration was reached
after 19.4  4.3 nicotine self-administration sessions (means 
SD). At stability, the average number of nicotine infusions/ses-
sion was 19.0 1.0, with an average nicotine intake of 0.5 0.1
mg  kg1  session1. Rate of responding was 111.0  8.5 and
9.1 1.7 active and inactive lever presses, respectively (means
SEM of the last three self-administration sessions before starting
the testing phase; data only from rats with correct VTA guide
cannulae placements, n 13).
On test sessions, CntxMII (10M) or aCSF were perfused for 15
min and rate of responding was recorded for the following hour.
Note that previous experiments (see above, Effects of different
delays between intra-VTA CntxMII perfusion and systemic
nicotine administration) showed that CntxMII could effectively
inhibit nicotine-elicited locomotion for at least 1 h after 15 min
perfusion.CntxMII (10M)perfused into theVTAthroughbilateral
guide cannulaewas able tomarkedly reduce responding for nicotine
self-administration(9.91.8numberofnicotine infusions/session)
compared with baseline sessions (18.4 1.4mean number of nico-
tine infusions/session of the last three self-administration sessions;
means  SEM) (Fig. 11A). Rate of responding decreased from
104.4  10.8 (baseline sessions) to 52.8  12.4 (CntxMII test ses-
sion) mean SEM active lever presses/session (Fig. 11B). The ob-
served decrease (
50%) in nicotine self-administration induced by
intra-VTA perfusion of CntxMII is comparable with that observed
in the same paradigm after the administration of other nicotinic
antagonists, such as mecamylamine and dihydro--erythroidine
(for review, see Lerman et al., 2007).
The statistical analysis performed by means of paired sample
Student’s t test on test session values  baseline session values
showed that intra-VTA 10 M CntxMII pretreatment signifi-
cantly decreased the number of nicotine infusions/session with
respect to aCSF pretreatment (t 2.84; p 0.016; df 11).
No significant changeswere observed for inactive lever presses
after CntxMII pretreatment (paired sample Student’s t test, t 
1.69; p  0.122; df  10) (Fig. 11B). A high number of inactive
lever presses during aCSF test session (179 presses/1 h) was ob-
served for subject CO2. Considering that the same subject did not
show significant changes during CntxMII session compared with
baseline (9.0 vs 5.7 inactive lever presses/1 h) and that the group
average for CntxMII test day was not significantly different from
baseline values, nonspecific effects of CntxMII perfusion on in-
active lever presses could be excluded.
Using the same bilateral perfusion protocol, no significant
effect of intra-VTA CntxMII (10 M) was observed on food-
maintained responding (Fig. 12). On test sessions, CntxMII or
aCSF were perfused for 15 min and rate of responding was re-
corded for the following hour. The 10MCntxMII perfusion into
the VTA was not able to significantly reduce responding for food
(45.3  7.6 number of food reinforcers/CntxMII test session vs
54.5  1.2 mean number of food reinforcers/session of the last
three baseline sessions) compared with aCSF perfusion (50.5 
3.3, number of food reinforcers/aCSF test session, vs 55.1 0.9,
mean number of food reinforcers/session of the last three base-
line sessions; paired sample Student’s t test on test  baseline
values, t 0.586, p 0.583, df 5).
In addition, CntxMII pretreatment was not able to alter the
number of either active or inactive lever presseswith respect to aCSF
Figure 9. Effects of intra-VTA perfusion (15min before rat placement into the activity cage)
of CntxMII (1 or 10 M) on novelty-elicited locomotion. Error bars indicate SEM. Statistical
analysiswas according to repeated-measures ANOVA. No significant group effectwas detected.
Group size: aCSF, 14 rats; CntxMII (1M), 6 rats; CntxMII (10M), 5 rats.
Figure 10. Effects of 10M CntxMII perfused for 15 min into the VTA on habituated loco-
motion elicited by nicotine (0.4 mg/kg base, i.p.) injected immediately after, 1 or 4 h after the
end of CntxMII perfusion. Mean values are shown. Error bars indicate SEM. Statistical analysis
was according to repeated-measures ANOVA; *p 0.05, **p 0.01 versus NicaCSF. Group
size: aCSF, 11 rats; 0 delay, 6 rats; 1 h delay, 7 rats; 4 h delay, 10 rats.
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pretreatment (active lever presses; CntxMII: 404.2  103.0/test vs
316 59.7/baseline; aCSF: 317.5 62.0/test vs 377.1 79.6/base-
line; paired sample Student’s t test, t  1.75, p  0.141, df  5;
inactive lever presses; CntxMII: 6.1 3.1/test vs 5.1 2.9/baseline;
aCSF: 14.4 8.6/test vs 7.8 3.2/baseline; paired sample Student’s
t test, t0.87, p 0.425, df 5) (Fig. 12).
The results of this experiment support the specificity of
CntxMII effects on nicotine self-administration and indicate that
the intra-VTA bilateral perfusion of CntxMII at the 10 M dose
does not cause nonspecific changes in lever pressing.
Discussion
62* nAChRs expressed in midbrain DA neurons
are heterogeneous
Present immunochemical analysis shows a partial regional heter-
ogeneity of nAChR subtypes in mesostriatal DA neurons.
Whereas 6* receptors expressed by nigrostriatal DA terminals
are almost exclusively 4623 receptors, the majority of 6*
receptors expressed by mesolimbic terminals are 623 recep-
tors. In addition, a minor population of 423 receptors is
expressed in the CPu. The much higher prevalence of receptors
with two 62 binding interfaces in ventral striatum may con-
tribute to explain the different sensitivity to systemic nicotine of
nigrostriatal andmesolimbic pathways (Di Chiara and Imperato,
1988; Janhunen and Ahtee, 2007). Purely 6 or mixed 46 re-
ceptors may have different pharmacological and physiological,
and perhaps also cell biology, properties. The mixed 462
receptor has higher affinity for nicotinic agonists than the 62
receptor (Salminen et al., 2007), and chronic nicotine (Perez et
al., 2008) has opposite effects on the expression of these subtypes
in the striatum. These findings may possibly explain the recent
evidence of a dominance of purely 6*-sensitive responses in the
nAc, whereas 4 responses dominate in the CPu (Exley et al.,
2008).
A second heterogeneity concerns nerve terminal versus cell
body/dendrite compartments of DA neurons. Although the
present study could not discriminate the substantia nigra from
the VTA and may therefore hide additional heterogeneities, the
present findings show that the cell body/dendrite compartment
contains peculiar nAChR subtypes. In fact, no receptors with
double 62 interfaces seem to exist in the ventral midbrain DA
neurons, whereas putative 22* receptors could be detected
only in DA neurons of this region. Although the low absolute
Figure 11. Effects of CntxMII on responding in rats trained to self-administer nicotine.
CntxMII (10 M) or aCSF were perfused into the VTA for 15 min before the start of the test
session. A, Number of nicotine infusions. The marks represent the number of infusions/1 h
session during the three last sessions (baseline) before the CntxMII (open circles) or aCSF (filled
circles) test sessions. B, Number of active and inactive lever presses. The marks represent the
number of active (circles) or inactive (triangles) lever presses/1 h session during the three last
sessions (baseline) before the CntxMII (open symbols) or aCSF (filled symbols) test sessions.
CntxMII (10 M) or aCSF were perfused for 15 min before the start of the test session. The
statistical analysis was performed by means of paired sample Student’s t test on test session
values  baseline session values; *p  0.05. Mean  SEM values are shown. n  12
rats/group.
Figure 12. Effects of CntxMII on food-maintained responding in rats. A, Number of food
reinforcers. Themarks represent thenumber of reinforcers/1 h sessionduring the three last sessions
(baseline) before theCntxMII (open circles) or aCSF (filled circles) test sessions.B, Number of active
and inactive lever presses. Themarks represent the number of active (circles) or inactive (trian-
gles) lever presses/1 h session during the three last sessions (baseline) before the CntxMII (open
symbols) or aCSF (filled symbols) test sessions. CntxMII (10M) or aCSF were perfused for 15
min before the start of the test session. The statistical analysis was performed by means of
paired sample Student’s t test on test session values baseline session values. No significant
group effect was detected. Mean SEM values are shown. n 6 rats/group.
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amount of Epi binding immunoprecipitated by 2 antibody
prompts some caution on this latter result, it should be noticed
that a previous paper showed that 2 mRNA is expressed by
midbrain DA neurons (Charpantier et al., 1998).
Differently from striatum, in ventral midbrain we obtained
evidence of 632* nAChR expression in non-DA neurons,
presumably ganglionic terminals in the MT. Instead, we did not
obtain evidence for 6* nAChR expression in a subpopulation of
GABA neurons, previously described in the substantia nigra pars
reticulata with electrophysiology coupled to single-cell PCR ap-
proach (Klink et al., 2001), perhaps because of its very low con-
centration. Finally, non-DA neurons of ventral midbrain express
substantial levels of 3, 4, and 3 subunits, which should be-
long to 334* receptors expressed by the fibers of the fascicu-
lus retroflexus, which, in addition, express 32(non-4)*
nAChRs (Whiteaker et al., 2002; Grady et al., 2009).
Overall, the present and previous results demonstrate that, in
the ventral midbrain, most 632* nAChRs are expressed by
DA cell bodies and/or dendrites, with a substantial minority of
this subtype expressed by retinal afferents in MT. 334* and,
to a more limited extent, 32* nAChRs are expressed by axons/
terminals of the habenulo-interpeduncular pathway. More dis-
criminative approaches, such as optic and electron microscopy,
are required to complete the complex picture of nAChR subtypes
in this region.
Intracerebrally perfused CntxMII and CntxPIA bind
62*/32* and62* nAChRs, respectively
A main issue has been to evaluate the effective concentration of
conotoxins perfused into the brain and therefore their selectivity
for nAChR subtypes. The experiment on 125I-CntxMII perfusion
shows that
5% of the toxin can cross the dialysis membrane in
present experimental conditions. This figure is slightly lower than
that of small molecules (10–15%) (Tang et al., 2003). An expo-
nential decrease of the toxin concentration takes place diffusing
into the tissue, so that the concentration at a distance of 1 mm
from the membrane becomes 1% or less. The studies on protein
binding of CntxMII in the brain show that10% of the toxin is
free and therefore available for binding to nAChRs. CntxMII and
CntxPIA antagonize nicotine effects at a concentration of 1 and
10 M in the perfusion liquid, respectively. We can reasonably
calculate that the effective intratissue concentration of CntxMII
and CntxPIA is between 5 and 1 nM and 50 and 10 nM, respec-
tively, within 1 mm far from the dialysis cannula. According to
the literature and present binding data, these concentrations are
selective for 62 binding interfaces. In self-administration ex-
periments, CntxMII was perfused at 10 M concentration and
may partially block 32* nAChRs, too.
62* nAChRs expressed in the VTA are necessary for
systemic nicotine effects on DA release, habituated
locomotion, and reinforcement
The main result of this study is that CntxMII and CntxPIA per-
fused into the VTA inhibit nicotine-elicited DA release in nAc
and habituated locomotion. In addition, intra-VTA CntxMII
pretreatment significantly reduces responding for nicotine self-
administration at an extent comparable with that previously ob-
tained with other nicotinic antagonists in the same paradigm.
This latter finding has been obtained with a valid rat model of
nicotine reinforcement behavior, under experimental and nico-
tine dosing conditions widely used for studying the reinforcing
effects of nicotine (Vezina et al., 2007; Markou et al., 2008). Al-
though preliminary, these data strongly suggest that VTA
CntxMII-sensitive receptors contribute to the activation of DA
mesolimbic pathway elicited by intravenously self-administered
nicotine.
Recently, Pons et al. (2008) reported that 6 knock-out mice
do not acquire acute intravenous nicotine self-administration, a
model of initiation of nicotine self-administration. Overall,
present and previous data on nicotine self-administration ob-
tained with different protocols (acute or chronic) in different
species (mice or rats) strongly support a major involvement of
VTA 6* nAChRs in nicotine-reinforcing properties.
Present and previous data point to the fact that CntxMII/
CntxPIA-sensitive receptors in the VTA consist of 62* nAChRs,
expressedbymidbrainDAneurons (see above). In addition,32*
nAChRs of the habenulo-interpeduncular system may in part
contribute to inhibition of nicotine self-administration, as sug-
gested by the implication of this pathway in reward processes
(Glick et al., 2006; Taraschenko et al., 2007; Morissette and Boye,
2008). Note, however, that available evidence points to a relevant
role of 34* rather than 32* nAChRs. Therefore, the present
findings strongly support the notion that 62* nAChRs ex-
pressed byDAneurons of theVTA are necessary forDA release in
nAc, locomotion, and reinforcement elicited by systemic nicotine
administration.
A functional role of 62* nAChRs expressed by DA mesos-
triatal neurons has been repeatedly demonstrated in ex vivo prep-
arations in both striatum and midbrain (Klink et al., 2001;
Champtiaux et al., 2003; Salminen et al., 2004, 2007; Drenan et
al., 2008; Exley et al., 2008;Meyer et al., 2008).However, previous
in vivo evidence for a physiological or pharmacological role of
these receptors was in part contradictory. In accordance with
present findings, intra-VTA infusion of anti-6 oligonucleotides
partially inhibits nicotine-elicited habituated locomotion in rats
(Le Nove`re et al., 1999), and mice expressing gain-of-function
6* nAChRs show spontaneous hyperlocomotion that is exag-
gerated by low dose of systemic nicotine (Drenan et al., 2008).
Instead, no significant change in systemic nicotine-elicited DA
release in nAc was detected in 6/ mice (Champtiaux et al.,
2003). Note, however, that the increased concentration of 42*
nAChRs detected in mesostriatal regions of 6/ mice may
compensate for the lack of 62* nAChRs (Champtiaux et al.,
2003).
The present results show that VTA 62* receptors are nec-
essary for someDA neuron-related effects of nicotine, but do not
exclude the contribution of (non-6)2* receptors or 7 recep-
tors (Schilstro¨m et al., 2000; Laviolette and van der Kooy, 2003;
Mameli-Engvall et al., 2006). As regards 2* nAChRs, whose fun-
damental role inmediating nicotine effects onDAneurons and nic-
otine reinforcement has been clearly established (Picciotto et al.,
1998;Maskos et al., 2005;Walters et al., 2006), a strong case has been
made for 42* nAChRs. Available evidence shows that systemic
nicotine-elicitedDA release and acute self-administration are ab-
sent if 4* receptors are deleted (Marubio et al., 2003; Pons et al.,
2008). An important role of 4* nAChRs is also suggested by the
evidence that activation of hypersensitive 4* nAChRs is sufficient
to support nicotine place preference (Tapper et al., 2004). Yet, at the
moment, the pharmacological evidence of the contribution of
42* receptors to maintenance of nicotine self-administration is
not conclusive, since the selectivity for42* with respect to62*
nAChRs of available nicotinic antagonists or partial agonists
(dihydro--erythroidine, SSR591813 [(5aS,8S,10aR)-5a,6,9,10-
tetrahydro,7H,11H-8,10a-methanopyrido[2,3:5,6]pyrano[2,3-d]
azepine], varenicline, UCI-30002 [N-(1,2,3,4-tetrahydro-1-naphthyl)-
4-nitroaniline]) (Corrigall et al., 1994; Cohen et al., 2003; Rollema et
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al., 2007; Yoshimura et al., 2007) is notwell established.Wepropose
that both 62 and 42 receptors are necessary for (at least some
of) the effects of nicotine on the DA system. Therefore, blockade of
either one or the other nAChR subtype strongly reduces or sup-
presses nicotine effects on the DA system.
Overall, the present experiments show that 62* nAChRs
expressed in the VTA are necessary for the effects of systemic
nicotine onDA release in the nAc, amain neurochemical target of
addictive drugs (Di Chiara, 2000; Wise, 2002), and nicotine self-
administration, a valid animal model of nicotine-reinforcing
properties. Since these receptors are expressed almost exclusively in
this brain region, 62*-selective compounds able to cross the
blood–brain barrier would be promising drugs to affect nicotine
addictive properties and, therefore, for the therapy of tobacco de-
pendence with higher selectivity for the DA system and potentially
fewer side effects than 42*-selective or subtype-nonselective
compounds.
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